Skip to content

D&A at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$594M-41.3%
Eli Lilly logo
Eli LillyLLY
$509M+9.9%
Pfizer logo
PfizerPFE
$1.61B-0.3%
Amgen logo
AmgenAMGN
$1.12B-19.5%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$2.35M+38.7%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$463K-25.6%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s D&A?
Erasca, Inc. (ERAS) reported D&A of $723K in Q1 2026.
How has Erasca, Inc.'s D&A changed year-over-year?
Erasca, Inc.'s D&A decreased by 12.0% year-over-year, from $822K to $723K.
What is the long-term trend for Erasca, Inc.'s D&A?
Over 4 years (2021 to 2025), Erasca, Inc.'s D&A has grown at a 39.1% compound annual growth rate (CAGR), from $829K to $3.11M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.